• DOI:10.2165/11634010-000000000-00000
Corpus ID: 20323687

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@article{Johnston2012FirstLineDT,
  title={First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis},
  author={J. Johnston and Tsz-Yin So},
  journal={Drugs},
  year={2012},
  volume={72},
  pages={1195-1211}
}

J. Johnston, Tsz-Yin So

Published 2012

Medicine

Drugs

Paediatric multiple sclerosis (MS) is defined as the onset of MS before the age of 18 years. Immunomodulatory disease-modifying therapies (i.e. the interferons [IFNs] and glatiramer acetate) are considered first-line treatments in adult patients with MS, but they are largely understudied in the paediatric population.IFNβ is a type 1 IFN produced by fibroblasts. The therapeutic effect achieved by IFNβ in MS is believed to be the result of a variety of mechanisms, including the inhibition of T… CONTINUE READING

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed